Novel PROTACs targeting tissue transglutaminase (TG2) suppress tumorigenicity of ovarian cancer cells.

Tissue transglutaminase (TG2), a multifunctional enzyme involved in protein crosslinking through transamidation, fibronectin-integrin interactions and GTP hydrolysis, is upregulated in cancer. Due to its diverse functions, TG2 has been a challenging therapeutic target. Here, we investigate the use of PROteolysis TArgeting Chimeras (PROTACs) to degrade TG2 and inhibit its tumor-promoting functions in ovarian cancer models. We describe a novel family of VHL based PROTACs using a ligand that binds to the TG2 fibronectin interacting domain and a thiol ether PEG linker. Three structurally related PROTACs-P374, P404, and P405-induced significant proteasome dependent TG2 degradation at 24 h (p < 0.05), with stable effects at 48 h. These compounds also potently inhibited cell adhesion and migration (p < 0.005), outside-in signaling, and blocked TG2 enzymatic activity (p < 0.001). An unbiased evaluation using reverse phase protein array of P374-treated cells revealed 136 differentially expressed proteins, including protein networks related to cell adhesion and involved in extracellular matrix (ECM) interactions. P374 and P405 reduced omental colonization in vivo and P374 inhibited intraperitoneal tumor dissemination and growth. Visium HD based spatial profiling of human ovarian tumors identified TG2 as a highly enriched protein at the tumors invasive edge and the interface with the ECM. Together, our findings put forward novel TG2-targeting PROTACs which effectively degrade TG2, impair its functions, and block in-vivo tumor dissemination. These results highlight the potential development of TG2 degraders towards therapeutic targeting in ovarian cancer.

• Publication year

  2025

• Venue

  European journal of medicinal chemistry

• Publication date

  2025-10-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejmech.2025.118228PMID 41061294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity.

  2024cited by this paper
• The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease

  2024cited by this paper
• The Role of Transglutaminase 2 in Cancer: An Update

  2024cited by this paper
• Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma

  2024cited by this paper
• Discovery of a Potent PROTAC Enables Targeting of FKBP51's Scaffolding Functions.

  2023cited by this paper
• Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2)

  2023cited by this paper
• Normal saline remodels the omentum and stimulates its receptivity for transcoelomic metastasis

  2023cited by this paper
• Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

  2023cited by this paper
• Tissue transglutaminase activates integrin-linked kinase and β-catenin in ovarian cancer

  2022cited by this paper
• Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.

  2022cited by this paper
• Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2

  2022cited by this paper
• The Outside-In Journey of Tissue Transglutaminase in Cancer

  2022cited by this paper
• Role of TG2 and TGF-β1 in the pathogenesis of human breast cancer

  2020cited by this paper
• The PROTAC technology in drug development

  2019cited by this paper
• BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

  2019cited by this paper
• Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

  2019cited by this paper
• Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

  2019cited by this paper
• Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

  2018cited by this paper
• Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

  2017cited by this paper
• Role of tissue transglutaminase-2 (TG2)-mediated aminylation in biological processes

  2017cited by this paper
• Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival

  2016cited by this paper
• Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression

  2015cited by this paper
• Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial–mesenchymal transition mediating pancreatic cancer cells invasion

  2014cited by this paper
• Small Molecule Inhibitors Target the Tissue Transglutaminase and Fibronectin Interaction

  2014cited by this paper
• Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

  2013cited by this paper
• Tissue transglutaminase regulates β‐catenin signaling through a c‐Src‐dependent mechanism

  2013cited by this paper
• Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells

  2012cited by this paper
• TG2, a novel extracellular protein with multiple functions

  2012cited by this paper
• Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer

  2012cited by this paper
• Recent advances in the development of tissue transglutaminase (TG2) inhibitors

  2011cited by this paper
• Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.

  2009cited by this paper
• Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity*

  2009cited by this paper
• Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.

  2008cited by this paper
• Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer

  2008cited by this paper
• Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells

  2008cited by this paper
• Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy

  2007cited by this paper
• Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.

  2007cited by this paper
• Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.

  2006cited by this paper
• Tissue transglutaminase (TG2)--a wound response enzyme.

  2006cited by this paper
• Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells

  2006cited by this paper
• Tissue transglutaminase (TG2) in cancer biology.

  2005cited by this paper
• Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.

  2005cited by this paper
• Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas

  2005cited by this paper
• Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses

  2004cited by this paper
• Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer

  2004cited by this paper
• Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

  2001cited by this paper

• No citing papers are available for this paper.